Akari Therapeutics PLC (AKTX)
1.36
-0.11
(-7.48%)
USD |
NASDAQ |
May 03, 16:00
1.39
+0.03
(+2.21%)
After-Hours: 20:00
Akari Therapeutics Total Liabilities (Quarterly): 4.584M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.584M |
| June 30, 2023 | 5.232M |
| June 30, 2022 | 3.045M |
| March 31, 2022 | 5.524M |
| December 31, 2021 | 6.093M |
| September 30, 2021 | 3.356M |
| June 30, 2021 | 3.242M |
| March 31, 2021 | 3.903M |
| December 31, 2020 | 5.220M |
| September 30, 2020 | 8.835M |
| June 30, 2020 | 11.11M |
| March 31, 2020 | 8.153M |
| December 31, 2019 | 6.472M |
| September 30, 2019 | 7.419M |
| June 30, 2019 | 6.523M |
| March 31, 2019 | 7.590M |
| December 31, 2018 | 4.918M |
| Date | Value |
|---|---|
| September 30, 2018 | 6.324M |
| June 30, 2018 | 8.493M |
| March 31, 2018 | 9.171M |
| December 31, 2017 | 11.90M |
| September 30, 2017 | 9.385M |
| June 30, 2017 | 9.201M |
| March 31, 2017 | 14.12M |
| December 31, 2016 | 11.77M |
| September 30, 2016 | 11.03M |
| June 30, 2016 | 17.05M |
| March 31, 2016 | 16.60M |
| December 31, 2015 | 21.17M |
| September 30, 2015 | 37.84M |
| June 30, 2015 | 1.987M |
| March 31, 2015 | 1.722M |
| December 31, 2014 | 1.171M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
3.045M
Minimum
Jun 2022
11.11M
Maximum
Jun 2020
5.914M
Average
5.524M
Median
Mar 2022
Total Liabilities (Quarterly) Benchmarks
| DBV Technologies SA | 42.80M |
| Cellectis SA | 249.58M |
| Adaptimmune Therapeutics PLC | 243.10M |
| Biodexa Pharmaceuticals Plc | 7.470M |
| NuCana PLC | 16.46M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 4.355M |
| Shareholders Equity (Quarterly) | -0.229M |